肺部疾病中的话题: 肺高血压
Alexander Kaysin1, Sunil Swami2, Oluwatoni Aluko2
1University of Maryland (UM) Capital Region Health Family Medicine Residency Program in Largo, MD.
FP essentials
|January 13, 2026
概括
肺高血压 (PH) 是一种严重的疾病,通过心声学和右心导管检查来诊断. 早期预防和向治疗,包括新药疗法,改善了患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 内部医学 内部医学
背景情况:
- 肺高血压 (PH) 是一种渐进性疾病,其特征是肺动脉高压.
- 早期诊断依赖于识别呼吸障碍和疲劳等症状,心声回声作为主要工具.
研究的目的:
- 概述PH的诊断标准,包括心声学和右心脏导管.
- 详细介绍PH的初级和二级预防策略.
- 对肺动脉高血压 (PAH) 的现有和新兴药物疗法进行审查.
主要方法:
- 通过右心导管检查证实了诊断 (肺动脉平均压力≥20 mm Hg,肺血管阻力>2木单位).
- 预防策略包括改变生活方式,控制风险因素 (高血压,糖尿病) 和环境暴露管理.
- 药物疗法审查包括向内甲素,前环素和氧化通路.
主要成果:
- 针对特定途径的药物治疗的进步改善了肺动脉高血压的结果.
- 建议在中度至重度的疾病中进行组合治疗;在晚期的PAH中使用肠道前列腺类药物.
- 右侧心力衰竭的管理包括流体管理,利尿剂,并考虑肺移植或息手术.
结论:
- 肺高血压的有效管理需要早期怀疑,准确的诊断和全面的预防策略.
- 新型药物治疗提供了更好的结果,结合疗法和根据疾病严重程度量身定制的先进治疗.
- 综合性支持性护理,包括营养和管理并发症,如右侧心力衰竭,对于PH患者至关重要.
更多相关视频
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
567
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
567
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
584
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
584
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
457
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
457
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
438
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
438
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
554
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
554
Other Pulmonary Disorders
1.5K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.5K


